SMA Research Platform

Explore SMA therapies and repurposing research with separate regulatory context, SMA evidence, research status and computational results. References, historical programmes and records awaiting source review remain available in their own views.

The treatment landscape includes SMN-directed therapies and muscle-directed adjuncts. Recent updates include intrathecal Itvisma and the US approval of ISEMBYLD (apitegromab-mstn) on 11 September 2026. Product eligibility, route, region and date matter: a clinical trial phase in another disease or a docking result is not evidence of SMA efficacy. Open each record for its sources and current statement limits.